首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   71201篇
  免费   7225篇
  国内免费   2582篇
耳鼻咽喉   223篇
儿科学   753篇
妇产科学   355篇
基础医学   3839篇
口腔科学   673篇
临床医学   6214篇
内科学   8043篇
皮肤病学   1213篇
神经病学   2813篇
特种医学   955篇
外国民族医学   7篇
外科学   4557篇
综合类   9031篇
现状与发展   6篇
一般理论   4篇
预防医学   4365篇
眼科学   780篇
药学   29539篇
  34篇
中国医学   3341篇
肿瘤学   4263篇
  2024年   137篇
  2023年   1171篇
  2022年   1515篇
  2021年   2646篇
  2020年   2746篇
  2019年   2664篇
  2018年   2714篇
  2017年   2958篇
  2016年   2737篇
  2015年   2735篇
  2014年   4659篇
  2013年   7479篇
  2012年   4645篇
  2011年   5792篇
  2010年   3965篇
  2009年   3600篇
  2008年   3308篇
  2007年   3202篇
  2006年   2895篇
  2005年   2569篇
  2004年   2200篇
  2003年   2009篇
  2002年   1532篇
  2001年   1468篇
  2000年   1158篇
  1999年   990篇
  1998年   866篇
  1997年   801篇
  1996年   671篇
  1995年   637篇
  1994年   546篇
  1993年   455篇
  1992年   502篇
  1991年   422篇
  1990年   345篇
  1989年   276篇
  1988年   278篇
  1987年   273篇
  1986年   209篇
  1985年   233篇
  1984年   183篇
  1983年   139篇
  1982年   126篇
  1981年   99篇
  1980年   77篇
  1979年   67篇
  1978年   76篇
  1977年   49篇
  1976年   57篇
  1975年   53篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Epilepsy is a common neurologic disorder, which is efficiently treated with carbamazepine and valproic acid. Moreover, Saudi Ministry of Health implemented a new E-system for Poison Control Centers called Awtar to enhance technology utilization in ensuring patients’ satisfaction and to improve treatment outcomes. Therefore, we conducted this study to assess appropriateness of indication of requests and therapeutic levels of carbamazepine and valproic acid in Tabuk area, North West Saudi Arabia. This is a retrospective observational study conducted in Poison Control & Forensic Chemistry Center, Tabuk, Saudi Arabia. Patients’ data were obtained for years 2018 and 2019. The blood levels of carbamazepine and valproic acid were measured by Therapeutic Drug Monitoring (TDM) Unit. We selected patients treated with either valproic acid or carbamazepine alone without any history of drug allergy. Data of 264 patients were extracted from Awtar E-system. Serum carbamazepine levels were within therapeutic range in 114 patients (75.50%), above-therapeutic range in 13 patients (8.61%) and sub-therapeutic levels in 24 patients (15.89%). Regarding serum valproic acid, it is within therapeutic range in 62 patients (54.87%), above-therapeutic range in 11 patients (9.73%) and sub-therapeutic levels in 40 patients (35.40%). In conclusion, this study gives information about partial appropriateness of usage of carbamazepine and low level of appropriateness of valproic acid. However, more efforts are needed to improve results of appropriateness of indication of antiepileptic drugs.  相似文献   
32.
33.
BackgroundNowadays surgery remains the gold standard of treatment for tongue cancer. Via a more clear and precise terminology, the glossectomy classification by Ansarin et al. facilitates shared communication between surgeons, allowing comparison between published research and improving surgical practice and patient care. To establish the association of glossectomies, according to their classification by Ansarin et al. with overall survival (OS), disease-free survival (DSF), and cause-specific survival (CSS) in tongue cancer, we conducted a systemic retrospective study on 300 consecutive patients affected by primary oral tongue cancer and treated with surgery at the European Institute of Oncology, IRCCS (IEO).MethodsThree hundred patients with tongue squamous cell carcinoma and treated at the Division of Otorhinolaryngology and Head and Neck Surgery of the European Institute of Oncology, IRCCS were cataloged according to the glossectomy classification. OS, DFS, and CSS were compared by surgical treatments.ResultsOS-5yrs was 80% for the type I glossectomy group, 75% for type II, 65% for type III, and 35% for type IV-V. DFS-5yrs was 74%, 60%, 55%, and 27%, respectively for I, II, III, and IV-V glossectomy group; CSS-5yrs was 82%, 80%, 72%, and 48%, respectively for I, II, III, and IV-V glossectomy group (p < 0.01).ConclusionsThis study confirmed that the application of the glossectomy classification was statistically correlated with patients' oncological outcomes.  相似文献   
34.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。  相似文献   
35.
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs.  相似文献   
36.
37.
目的    应用锥形束CT(cone beam CT,CBCT)测量种植区牙槽骨质量并结合Lekholm和Zarb分类法对骨质量分类方法进行改良,以期为提高牙槽骨质量分类的准确性提供指导。方法    选择2015年10月至2017年10月在呼和浩特市口腔医院种植科进行种植修复的196例患者术前CBCT影像资料,应用 Invivo5诊断设计软件测量306个种植位点的牙槽骨皮质骨厚度和松质骨密度(皮质骨与松质骨的CT值差值),以Lekholm和Zarb分类法为基础结合测量数据对骨质量进行改良后的量化分类。结果    牙槽骨皮质骨厚度为0.18 ~ 2.89 mm,中位数为0.92 mm。皮质骨与松质骨的CT值差值为88.5 ~ 667.8 HU,应用百分位数法找到33.3%和66.6%对应的数值分别为297.8 HU和356.1 HU。依据此数据结合Lekholm和Zarb分类法将196例患者的306个种植位点骨质量分为4类,其中Ⅰ类骨种植位点46个(占15.0%),Ⅱ类骨104个(占34.0%),Ⅲ类骨114个(占37.3%),Ⅳ类骨42个(占13.7%)。结论    结合Lekholm和Zarb分类法,应用CBCT测量种植区牙槽骨质量并进行分类方法的改良,可为临床医生术前评估牙槽骨质量提供一定参考。  相似文献   
38.
39.
The epithelial remnants of tooth development give rise to an impressive range of cystic lesions, termed odontogenic cysts. They are classified based on their distinct clinical, radiological and histological features, a process that has not been without controversy. We will attempt to explain the basis of the debate behind the changing classification of odontogenic cysts, describing their aetiology, clinical and histological features, along with common pitfalls that can confuse the diagnostic process. More common diagnostic challenges, such as the effects of inflammation and mucous change, will be explored in detail. An attempt will be made to distil the diagnostic process into simple algorithmic steps to narrow down the differential diagnoses of this fascinating group of lesions. We will demonstrate the importance of careful consideration of the clinical and radiological features that can help prevent misclassification, ensuring appropriate management and follow-up for this diverse group of lesions.  相似文献   
40.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号